Sanofi, RadioMedix, and Orano Med have partnered to advance AlphaMedixTM, a treatment for a rare cancer known as neuroendocrine tumors (NETs).
AlphaMedixTM, a radiopharmaceutical, employs a unique peptide to target somatostatin receptors on NETs. This peptide is combined with lead-212 (212Pb), which releases alpha particles to destroy cancerous cells.
AlphaMedixTM has shown promising results in clinical trials, exhibiting a favorable safety profile and significant tumor reduction. Its potential as a transformative treatment has led to Breakthrough Therapy Designation from the FDA.
Dietmar Berger, Chief Medical Officer at Sanofi, emphasizes the significance of radioligand therapies, including AlphaMedixTM, for treating rare cancers. The collaboration with RadioMedix and Orano Med aligns with Sanofi’s commitment to innovation in cancer care.
RadioMedix, a pioneer in radioligand therapy, developed AlphaMedixTM and believes it will revolutionize nuclear oncology. The high energy and short path length of alpha particles overcome the limitations of existing beta emitter therapies.
Orano Med, specializing in 212Pb production, brings expertise in manufacturing and distribution. Their contribution underscores the importance of this partnership in bringing AlphaMedixTM to patients globally.
The collaboration between Sanofi, RadioMedix, and Orano Med aims to provide patients with access to a potentially life-saving therapy. By leveraging innovative technologies and combining expertise, they strive to make a meaningful difference in treating rare cancers.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
